Home > Boards > US Listed > Biotechs > Verastem (VSTM)

Fairly decent guidance plus more in the pipeline

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jimmy667 Member Profile
 
Followed By 32
Posts 2,983
Boards Moderated 0
Alias Born 10/20/15
160x600 placeholder
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting Business Wire - 6/17/2019 7:00:00 AM
Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference Business Wire - 5/30/2019 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/20/2019 5:23:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 4:22:02 PM
Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference Business Wire - 5/16/2019 7:00:00 AM
Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study Business Wire - 5/15/2019 5:16:00 PM
Verastem Oncology Reports First Quarter 2019 Financial Results Business Wire - 5/9/2019 4:05:00 PM
Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019 Business Wire - 5/2/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2019 4:22:15 PM
Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility Business Wire - 4/23/2019 4:05:00 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/8/2019 4:13:23 PM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 4/4/2019 4:05:00 PM
Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire - 4/2/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/19/2019 4:14:21 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 3/18/2019 6:10:17 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/12/2019 4:28:34 PM
Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments Business Wire - 3/12/2019 4:08:00 PM
Verastem Oncology to Present at Upcoming Investor Conferences Business Wire - 3/12/2019 7:00:00 AM
Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Mali... Business Wire - 3/7/2019 5:01:00 PM
Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) in Patients with CLL/SLL Who Have Progresse... Business Wire - 3/4/2019 7:00:00 AM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 3/1/2019 4:49:00 PM
Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019 Business Wire - 2/26/2019 7:00:00 AM
Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference Business Wire - 2/21/2019 7:00:00 AM
CORRECTING and REPLACING Verastem Oncology Announces Key Management Appointments Business Wire - 2/20/2019 8:43:00 AM
Verastem Oncology Announces Key Management Appointments Business Wire - 2/20/2019 7:00:00 AM
jimmy667   Thursday, 05/09/19 06:11:52 PM
Re: DrHarleyboy post# 344
Post # of 393 
Fairly decent guidance plus more in the pipeline and clinical readout before years end. Partnerships and collaborations in 5he works. $211 million in cash more that twice the after market Market Cap of the whole Company. Full year revenue for the current approved drug $10 million. That alone should justify the After Market MCap without the $211 mil cash. Add in the fact more trials underway for an already approved for one indication drug (easier path to approval) any plenty of cash and I can see Sell Side Wall street put a one year target of $400 mil MCap or $5.60 a share. Price targets are currently low $5 mid $8.80 high $14.
Also there are 18 million shares short. When will they cover to take their profits and free up capital to move on to an over priced target?
This After market was overdone. I bought in here. I am looking for a significant bounce as shorts buy to cover to take profits. This could be a great short term long trade and a fairly derisked intermediate trade going into the next round of clinical trial readouts. Certainly not selling into this over reaction. I feel this may have been priced in this week already and that tomorrow will be a relief rally and spark a short covering bounce as well. This stock is 56% owned by institutions they will not be flummoxed by this basically par earnings report. Sales are UP 38% from last quarter and acellerating and moving into international markets soon by partners.
How many times have we seen After Market tanks turn into price rise the next day? 24.6% short or 18 million shares, wrap your mind around that.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist